GlassScriptPhysician profile
Andrew Schneider
NPI 1932120219
$770.98
in general payments reported to CMS, 2019-2025
15 companies · $73.00 in 2025
The $73.00 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $128 · 2021: $39.62 · 2022: $124 · 2023: $107 · 2024: $60.04 · 2025: $73.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.72 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $215.92 | 2019-2022 | |
| Abbvie INC. | $151.14 | 2023-2025 | Qulipta, Ubrelvy |
| E.R. Squibb & Sons, L.L.C. | $111.57 | 2022 | |
| Allergan, INC. | $47.01 | 2019 | |
| Genentech, INC. | $46.75 | 2023 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $46.14 | 2019-2020 | |
| Biogen, INC. | $24.92 | 2020 | |
| Kyowa Kirin, INC. | $21.23 | 2019 | |
| Acorda Therapeutics, INC | $20.03 | 2019 | |
| Janssen Biotech, INC. | $17.97 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Aprecia Pharmaceuticals, LLC | $16.69 | 2020 | |
| Lilly USA, LLC | $16.69 | 2020 | |
| Pfizer INC. | $11.16 | 2019 | |
| Aucta Pharmaceuticals, INC. | $5.86 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.